GlassScriptPhysician profile
Brooke Morgan
NPI 1306324033
$790.48
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $535 · 2023: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $255.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $154.34 | 2022-2023 | Hetlioz |
| Pfizer INC. | $80.12 | 2022-2023 | |
| Lilly USA, LLC | $70.51 | 2022-2023 | Jardiance, Emgality |
| Glaxosmithkline, LLC. | $58.57 | 2022-2023 | Trelegy Ellipta |
| Abbvie INC. | $52.39 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.01 | 2022-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $47.88 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $45.33 | 2022-2023 | Farxiga |
| Mylan Specialty L.P. | $45.01 | 2022 | |
| Novo Nordisk INC | $40.99 | 2022-2023 | Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company LTD. | $28.23 | 2022 | |
| Exeltis, USA INC. | $24.47 | 2022 | |
| Amgen INC. | $22.12 | 2023 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $19.26 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.02 | 2023 | Gvoke Hypopen |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $17.41 | 2022 | |
| Antares Pharma, INC. | $16.82 | 2023 | Nocdurna, Xyosted, Tlando |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.